Corneal response to canakinumab in cryopyrin associated periodic fever syndrome by Tsatos, M. et al.
LETTERS
Corneal response to
Canakinumab in Cryopyrin
associated periodic
fever syndrome
We describe the cases of a 15-year-old girl
and her father. She ﬁrst presented at the
age of 9 to Southampton University
Hospital Ophthalmology department with
recurrent attacks of iritis and corneal inﬁl-
trate denser in the left eye compared to the
right (ﬁgure 1). Her past medical history
suggested that her condition started in the
neonatal period when her immunisations
were missed as she developed a rash at
8 weeks. She regularly experienced rashes
and high fevers with some episodes requir-
ing hospital admission.
At the ocular inﬂammatory stage of her
condition, rheumatological assessment
revealed tenderness in her feet, ankles and
knees, and combined with the ophthalmic
presentation, a diagnosis of juvenile idio-
pathic arthritis was made. MRI and ultra-
sound scans showed no evidence of
synovitis. The severity of her arthritis was
related to the exacerbations of her ocular
features. The patient’s inﬂammatory
markers were all negative. She was managed
with NSAIDS (naproxen) with mild relief.
Since the age of 9 years, she also
experienced episodic mouth ulcers occur-
ring every 2 to 3 months lasting for
3 weeks. The patient was initially started
on colchicine, which was discontinued
after a vasovagal episode.
The patient’s father gave a similar
medical history. He developed eye pro-
blems in childhood, associated with arth-
ritis at 5 years of age with erythematous
skin rashes. He regularly developed mouth
ulcers when tired. His mother also suffered
from eye problems throughout her life.
At the age of 9 years old, she ﬁrst
visited the eye clinic with red eyes and
photophobia. Corneal assessment revealed
bilateral central corneal stromal opaciﬁca-
tion (denser in the left eye) and anterior
uveitis (ﬁgure 1), and treated with a taper-
ing dose of topical steroids. After ﬁve
further visits to the eye department and
paediatric rheumatology with similar
symptomatology that suggested an autoin-
ﬂammatory syndrome with autosomal
dominant pattern inconsistent with her
previous diagnosis, blood samples of
both the patient and her father were sent
to the National Amyloidosis Centre for
investigation of underlying periodic fever
syndrome. This conﬁrmed cryopyrin-
associated periodic syndrome (CAPS)
mutation in exon 3 of NLRP3 gene and
treatment with canakinumab (IL-1 recep-
tor antagonist) was started after a negative
QuantiFERON investigation. At this
point, the patient’s vision had dropped to
0.62 LogMar in both eyes from 0.12
LogMar at the patient’s ﬁrst visit.
A mutation of the NLRP3 gene that
encodes for cryopyrin causes the cryo-
pyrin inﬂammasome to constantly over-
produce IL-1β instead of only in response
to infections. This overproduction of
IL-1β causes many CAPS symptoms to be
present at birth or in early infancy, and
persist or increase throughout life.1
After initiation of canakinumab, the
corneal inﬁltrate reduced in density and by
6 months only a faint scar was present in
both eyes (ﬁgure 2) with corresponding
improvement in visual acuity from 0.62
LogMar (uncorrected and pinhole) pretreat-
ment to 0.28 uncorrected and 0.14 pinhole.
Cryopyrin Associated Periodic Syndromes
are a rare, hereditary group of inﬂammatory
disorders that comprise three conditions:
familial cold autoinﬂammatory syndrome
(FCAS) with the mildest phenotype,
Muckle-Wells syndrome (MWS), and
neonatal-onset multisystem inﬂammatory
disease (MONID) with the most severe
form of the disease.2 It is estimated that
there are 1–2 cases out of 1 million inhabi-
tants in the USA and 1/360 000 in France.3
CAPS are caused by autosomal dominant
gain-of-function mutations in the NLRP3
gene, located on chromosome 1q44. Char-
acteristic features of CAPS include non-
pruritic, migratory, atypical urticarial rash
on the trunk and limbs.2 Neurological fea-
tures include headaches, progressive hearing
loss, raised intracranial pressure and menin-
gitis.4 Common ophthalmic manifestations
include conjunctivitis, uveitis, and more
rarely, optic disc swelling. Rheumatological
features include pain and inﬂammation of
usually larger joints associated with endo-
chondrial ossiﬁcation.3 Systemic amyloid-
osis occurs in about 25% of CAPS patients,
affecting primarily the kidneys.1
Canakinumab is an IL-1β fully human,
monoclonal antibody that is speciﬁc for
IL-1β and not other members of the IL-1
family.3 Canakinumab has been FDA
approved for CAPS in adults and children
older than 4 years old. It has a half-life of
28 to 30 days, and therefore, has a con-
venient dosing schedule by subcutaneous
injection every 8 weeks.
Corneal inﬁltrates associated with CAPS
have been recently described and treated
with anakira (interleukin-1 antagonist)
and penetrating keratoplasty.4 5 To the
best of our knowledge, this is the ﬁrst
CAPS case with corneal involvement that
resolved with canakinumab treatment,
leading to restoration of the patient’s
reduced visual acuity.
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Figure 1 Before the initiation of canakinumab treatment. Access the article online to view this
ﬁgure in colour.
Figure 2 Six months after the beginning of canakinumab treatment. Only a faint scar is visible.
Access the article online to view this ﬁgure in colour.
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